Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
HIV Prevention Access Strategies Through Collaborative Partnerships in South Africa
HIV prevention access strategies have reached a pivotal moment in South Africa with the imminent launch of lenacapavir, a long-acting injectable administered twice yearly. This coordinated effort directly confronts the country’s immense HIV burden, including 7.8 million people living with the vir...
Cancer Productivity Disparities in the Asia-Pacific Region
New research exposes a deepening divide in cancer productivity Asia-Pacific, where middle-income countries face rapidly escalating productivity losses from premature cancer deaths and disability, while high-income economies have begun to stabilise their burdens. Between 2010 and 2022, indirect ec...
Generative AI Diagnosis in Neurology Enhances Non-Specialist Accuracy
Generative AI diagnosis is stepping into neurology with striking results. In a new study, ChatGPT-4o reached 65.5% accuracy for the correct leading diagnosis in challenging polyneuropathy cases, statistically matching non-specialist neurologists (63%) while trailing specialists (74%). The model o...